CD200R1, Fc Fusion, Avi-Tag Recombinant

Catalog #

102032

$320 *

Size: 100 µg

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human CD200R1 (cluster of differentiation 200 receptor 1), encompassing extracellular amino acids 29-265. This construct contains a C-terminal Fc domain from IgG1 followed by an Avi-Tag™. This protein was affinity purified.

●

Synonyms

Cell surface glycoprotein CD200 receptor 1, CD200 cell surface glycoprotein receptor, Cell surface glycoprotein OX2 receptor 1, CD200R, CRTR2, MOX2R, OX2R

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

Product Info

Storage and Usage

Citations

Species

Human

Construct

CD200R1 (29-265-Fc(lgG1)-Avi)

Host Species/Expression System

HEK293

Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

55 kDa + glycans

Amino Acids

29-265

Glycosylation

This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Genbank #

NM_138806.4

UniProt #

Q8TD46

Tag(s)

C-terminal FC, Avi-Tag™

Background

CD200R1 (cluster of differentiation 200 receptor 1), also known as OX-2R, is a transmembrane glycoprotein. It is found in cells of the myeloid and lymphoid lineage, such as CD4⁺ cells. It acts as immune inhibitory receptor, but contrary to other proteins with the same function, it does exhibit an ITIM (tyrosine-based inhibitory motif) domain. When bound to CD200 contributes to the formation of an immunosuppressive TEM (tumor microenvironment), via a Dok1 (docking protein 1), Dok2 and RasGAP dependent mechanism, leading to T cell responses inhibition, NK cell cytotoxicity decrease, potentiation of Treg cell expansion and decrease of other immune responses to cancer cells. In addition to cancer, CD200 is linked to auto-immune disorders, inflammation, infection, graft survival and cancer. Samalizumab, an anti-CD200 monoclonal antibody, has resulted in positive outcomes when used in patients suffering from CLL (chronic lymphocytic leukemia) and MM (multiple myeloma). Inhibition of the interaction between CD200 and CD200R1 may thus be beneficial as a new therapy approach in CD200-related diseases.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

●

Datasheets/Protocols

102032 Lot 240109

Datasheets provide example lot-specific information. Contact us to request information on currently available lots.

● General Protocols

● FAQs

● Contact Technical Service

●

CD200R1, Fc Fusion, Avi-Tag Recombinant

PRODUCTS

SERVICES

RESOURCES

COMPANY